Loading…
Uterine Fibroid Research and Education Act of 2020
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Uterine Fibroid Research and Education Act of 2020 This bill directs specified components of the Department of Health and Human Services to take certain actions to address uterine fibroids (i.e., muscular tumors that grow in the wall of the uterus and may cause pain, heavy menstrual bleeding, and reproductive issues). Specifically, the National Institutes of Health (NIH), working through the Office of Research on Women's Health, must undertake research activities on uterine fibroids. In carrying out this research, the office must coordinate with specified components of the NIH and other federal agencies. In addition, the Centers for Medicare & Medicaid Services must (1) collect data from Medicaid and the Children's Health Insurance Program about treatment and services related to uterine fibroids, and (2) develop a report in coordination with federal partners on federal and state expenditures for these treatments and services. Additionally, the Centers for Disease Control and Prevention (CDC), the Health Resources Service Administration (HRSA), and the Agency for Healthcare Research and Quality (AHRQ) must disseminate information about uterine fibroids, including the elevated risk for minority women and information regarding available treatments. Specifically, the CDC shall disseminate the information to the public, while HRSA and AHRQ shall disseminate it to health care providers.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2020 · third_quarter · Health Issues
Patient access to drug treatment therapies; and drug cost and drug pricing reform efforts. H.R.3 - Lower Drug Costs Now Act of 2019 S.2543, Prescription Drug Pricing Reduction Act of 2019 H.R.6383 - Uterine Fibroid Research and Education Act of 2020 S.4397 - Uterine Fibroid Research and Education Act of 2020
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Health Insurance Coverage (general); Health Disparities (general); Breastfeeding (general); Assisted Reproductive Technology (general); Smoking Cessation (general); Substance Use Disorder (general); Gynecologic Cancer (general); Gynecologic Devices (general); Reproductive Health (general); Intimate Partner Violence (general); Gun Violence (general); Immunization (general); Breast Cancer (general); Medical Liability Reform (general); Health IT (general); Patient-Physician Relationship (general); Child Welfare (general); Prematurity (general); Maternal Mortality and Morbidity (general); Graduate Medical Education (general); Contraception (general); Abortion (general); Indian Health (general); Teaching Health Centers Graduate Medical Education (general); Community Health Centers (general); National Health Service Corps (general); Special Diabetes Program (general); Special Diabetes Program for Indians (general); Sexuality Education (general); Teen Pregnancy Prevention Program (general); Personal Responsibility Education Program (general); Research in Pregnant and Breastfeeding Women (general); Health Care Reform (general); Title X Family Planning Program (general); Womens Preventive Services (general); Administrative Burden (general); Surprise Billing (general); Pediatric Loan Repayment Program (general); COVID-19 Response (general); Personal Protective Equipment (general); Risk Evaluation and Mitigation Strategies (general); Data Collection (general); Health Equity (general); Pregnancy Risk Assessment Monitoring System (CDC); Provider Relief Fund (general); Maternal Mental Health (general); Violence Against Women Act (general); Secretarys Advisory Committee on Infant Mortality (general); COVID-19 Vaccine (general); H.R. 2975/S. 1645, Womens Health Protection Act; S. 1895, Lower Health Care Costs Act; H.R. 2862/S. 1619, VACCINES Act; implementation of P.L. 115-344, Preventing Maternal Deaths Act; implementation of P.L. 115-320, Improving Access to Maternity Care Act; S. 2586, Maternal Outcomes Matter Act; HR 3630, No Surprises Act; HR 3502, Protecting People From Surprise Medical Bills Act; H.R. 4495, Maternal Health Quality Improvement Act of 2019; H.R. 5640/S. 3152, the Data Mapping to Save Moms Lives Act; H.R. 6142/ S. 3424, the Black Maternal Health Momnibus Act of 2020 implementation of P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; implementation of P.L. 116-127, the Families First Coronavirus Response Act; implementation of P.L. 116-136, the Coronavirus Aid, Relief, and Economic Security Act; implementation of P.L. 116-139, Paycheck Protection Program and Health Care Enhancement Act; H.R. 7059 the Coronavirus Provider Protection Act; H.R. 6953/ S. 3763 the Pandemic Responder Service Award Act; H.R. 6697, the Local Chamber, Tourism, and 501(c)(6) Protection Act; S.___, the Health, Economic Assistance, Liability Protection, and Schools Act; H.R. 2694, the Pregnant Workers Fairness Act; H.R. 8027, the Maternal Health Pandemic Response Act; HRes 1069/ SRes 655, Declaring racism a public health crisis; S. 4269 the Mothers and Newborns Success Act; S. 4349, Lorna Breen Health Care Provider Protection Act; H.R. 6701/S. 3595, Ensuring Understanding of COVID-19 to Protect Public Health Act; H.R. 8061/S. 4737, Community Immunity During COVID-19 Act; H.R. 8958/ S.4949, Supporting Best Practices for Healthy Moms Act; S.4863, HEALTH for MOM Act of 2020; H.R. 6383, Uterine Fibroid Research and Education Act; S.4859, Connected MOM Act.
Client expense: $147,955 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Indian Health Service, Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Substance Abuse & Mental Health Services Administration (SAMHSA), U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office
2020 · fourth_quarter · Health Issues
Issues related to patient access Issues related to pharmaceutical manufacturing Issues related to treatment of endometriosis Patent reform - S. 1416 - Affordable Prescriptions for Patients Act of 2019 Medicare Part D H.R. 748 CARES Act - Issues related to COVID-19 relief S. 4397/H.R.6383 - Uterine Fibroid Research and Education Act of 2020 H.R.133 - Consolidated Appropriations Act, 2021
Client expense: Not reported · Firm income: $60,000
Government targets: Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Economic Council (NEC), SENATE, U.S. Trade Representative (USTR)
2020 · fourth_quarter · Health Issues
Issues related to patient access Issues related to pharmaceutical manufacturing Issues related to treatment of endometriosis Patent reform - S. 1416 - Affordable Prescriptions for Patients Act of 2019 Medicare Part D H.R. 748 CARES Act - Issues related to COVID-19 relief S. 4397/H.R.6383 - Uterine Fibroid Research and Education Act of 2020 H.R.133 - Consolidated Appropriations Act, 2021
Client expense: Not reported · Firm income: $60,000
Government targets: Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Economic Council (NEC), SENATE, U.S. Trade Representative (USTR)
2020 · fourth_quarter · Health Issues
Patient access to drug treatment therapies; and drug cost and drug pricing reform efforts. H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 H.R.6383 - Uterine Fibroid Research and Education Act of 2020 S.4397 - Uterine Fibroid Research and Education Act of 2020
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 H.R.7647, To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule
Client expense: $650,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Council of Economic Advisers (CEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
2020 · third_quarter · Health Issues
Patient access to drug treatment therapies; and drug cost and drug pricing reform efforts. H.R.3 - Lower Drug Costs Now Act of 2019 S.2543, Prescription Drug Pricing Reduction Act of 2019 H.R.6383 - Uterine Fibroid Research and Education Act of 2020 S.4397 - Uterine Fibroid Research and Education Act of 2020
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 H.R.7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage. 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule
Client expense: $1,430,000 · Firm income: Not reported
Government targets: Council of Economic Advisers (CEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Health Issues
Issues related to patient access Issues related to pharmaceutical manufacturing Issues related to treatment of endometriosis Patent reform - S. 1416 - Affordable Prescriptions for Patients Act of 2019 Medicare Part D H.R. 748 CARES Act - Issues related to COVID-19 relief S. 4397/H.R.6383 - Uterine Fibroid Research and Education Act of 2020
Client expense: Not reported · Firm income: $60,000
2020 · second_quarter · Health Issues
Health Insurance Coverage (general); Health Disparities (general); Breastfeeding (general); Assisted Reproductive Technology (general); Smoking Cessation (general); Substance Use Disorder (general); Gynecologic Cancer (general); Gynecologic Devices (general); Reproductive Health (general); Intimate Partner Violence (general); Gun Violence (general); Immunization (general); Breast Cancer (general); E-Cigarettes (general); Medical Liability Reform (general); Health IT (general); Patient-Physician Relationship (general); Conscience Refusals (general); Child Welfare (general); Prematurity (general); Maternal Mortality and Morbidity (general); Graduate Medical Education (general); Contraception (general); Abortion (general); Indian Health (general); Teaching Health Centers Graduate Medical Education (general); Community Health Centers (general); National Health Service Corps (general); Special Diabetes Program (general); Special Diabetes Program for Indians (general); Sexuality Education (general); Teen Pregnancy Prevention Program (general); Personal Responsibility Education Program (general); Research in Pregnant and Breastfeeding Women (general); Health Care Reform (general); Title X Family Planning Program (general); Womens Preventive Services (general); Drug Pricing (general); Administrative Burden (general); Surprise Billing (general); Pediatric Loan Repayment Program (general);COVID-19 Response (general); Personal Protective Equipment (general); Risk Evaluation and Mitigation Strategies (general); Data Collection (general); Health Equity (general); Maternal Mental Health (general);; Violence Against Women Act (general); Secretarys Advisory Committee on Infant Mortality (general); H.R. 2975/S. 1645, Womens Health Protection Act; S. 1895, Lower Health Care Costs Act; H.R. 2862/S. 1619, VACCINES Act; implementation of P.L. 115-344, Preventing Maternal Deaths Act; implementation of P.L. 115-320, Improving Access to Maternity Care Act; S. 2586, Maternal Outcomes Matter Act; HR 3630, No Surprises Act; HR 3502, Protecting People From Surprise Medical Bills Act; H.R. 4495, Maternal Health Quality Improvement Act of 2019; H.R. 5640/S. 3152, the Data Mapping to Save Moms Lives Act; H.R. 6142/ S. 3424, the Black Maternal Health Momnibus Act of 2020; H.R. 6159, Kids Access to Primary Care Act of 2020; S. 4088, Ensuring Access to Primary Care for Women & Children Act; H.R. 6383, Uterine Fibroid Research and Education Act of 2020; implementation of P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; implementation of P.L. 116-127, the Families First Coronavirus Response Act; implementation of P.L. 116-136, the Coronavirus Aid, Relief, and Economic Security Act; H.R. 266, Paycheck Protection Program and Health Care Enhancement Act; H.R. 6800, the Heroes Act; H.R. 1425, the Affordable Care Act Enhancement Act; H.R. 7059 the Coronavirus Provider Protection Act; H.R. 6953/ S. 3763 the Pandemic Responder Service Award Act; H.R. 6697, the Local Chamber, Tourism, and 501(c)(6) Protection Act; H.Res 137/ S. Res 154, Supporting the designation of the week of April 11 through April 17, 2019 as "Black Maternal Health Week".
2020 · second_quarter · Health Issues
H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule
Client expense: $670,000 · Firm income: Not reported
Government targets: Council of Economic Advisers (CEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
| Democratic |
| MA |
| Barbara Lee | Democratic | CA |
| Bennie G. Thompson | Democratic | MS |
| Bobby L. Rush | Democratic | IL |
| Bonnie Watson Coleman | Democratic | NJ |
| Brenda L. Lawrence | Democratic | MI |
| Cedric L. Richmond | Democratic | LA |
| Danny K. Davis | Democratic | IL |
| Darren Soto | Democratic | FL |
| David Scott | Democratic | GA |
| Dina Titus | Democratic | NV |
| Eddie Bernice Johnson | Democratic | TX |
| Eleanor Holmes Norton | Democratic | DC |
| Emanuel Cleaver | Democratic | MO |
| G. K. Butterfield | Democratic | NC |
| Gregory W. Meeks | Democratic | NY |
| Hakeem S. Jeffries | Democratic | NY |
| Henry C. "Hank" Johnson, Jr. | Democratic | GA |
| James E. Clyburn | Democratic | SC |
| Karen Bass | Democratic | CA |
| Lucy McBath | Democratic | GA |
| Marcia L. Fudge | Democratic | OH |
| Michael F. Q. San Nicolas | Democratic | GU |
| Nanette Diaz Barragán | Democratic | CA |
| Nydia M. Velázquez | Democratic | NY |
| Raúl M. Grijalva | Democratic | AZ |
| Robin L. Kelly | Democratic | IL |
| Ruben Gallego | Democratic | AZ |
| Sanford D. Bishop, Jr. | Democratic | GA |
| Sheila Jackson Lee | Democratic | TX |
| Stacey E. Plaskett | Democratic | VI |
| Terri A. Sewell | Democratic | AL |
| Tony Cárdenas | Democratic | CA |
| Vicente Gonzalez | Democratic | TX |
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
Client expense: $416,756 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Indian Health Service, Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Substance Abuse & Mental Health Services Administration (SAMHSA), U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office